Eli Lilly and Company LLY announced that its board of directors approved a new $15 billion share buyback plan. The earlier $5 billion stock repurchase plan ended in the fourth quarter of 2024.The board...
AstraZeneca AZN announced that the FDA has accepted and granted priority review to its supplemental biologics license application (sBLA) seeking expanded use of its blockbuster drug, Imfinzi (durvalumab),...
The biotech industry has lagged the broader market so far in 2024. The SPDR S&P Biotech ETF, an industry benchmark, is up 9% this year compared to 28% for the S&P 500 . Will that trend continue in 2025?...
Jeffrey Hessekiel, the EVP & General Counsel of $EXEL ($EXEL), sold 60,000 shares of the company on 11-29-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately...
Patrick J. Haley, the EVP of $EXEL ($EXEL), sold 10,000 shares of the company on 11-22-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 3.5% of their shares....
The price could be right for these stocks.
EXEL earnings call for the period ending September 30, 2024.
For Immediate ReleaseChicago, IL – October 25, 2024 – Today, Zacks Equity Research discusses Exelixis, Inc, EXEL, Blueprint Medicines BPMC, CRISPR Therapeutics CRSP, Amicus Therapeutics FOLD and Verona...
It has been a decent year for the biotech industry so far, buoyed by new drug approvals and positive regulatory/pipeline updates. The third-quarter earnings season has just kicked off, with most major...